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Abstract	description:	Cancer	is	a	disease	that	has	killed	millions	and	cost	trillions.	It	
is	a	tragic	disease,	and	while	the	treatment	used	may	help	fight	cancer,	potential	
long-lasting	damage	is	inflicted	onto	the	heart.	Chemotherapies	are	widespread	
drugs	used	to	treat	any	and	all	kinds	of	cancer.	There	are	many	different	classes	
including,	but	not	limited	to,	the	anthracyclines,	taxanes,	monoclonal	antibodies,	
alkylating	agents,	tyrosine	kinases,	and	antiestrogens.	For	patients	with	breast	
cancer,	there	are	about	69	different	chemotherapies	approved	for	treatment,	and	
they	are	all	from	a	variety	of	different	classes.	However,	most	of	the	classes	of	
chemotherapies	are	associated	with	some	kind	of	cardiotoxicity.	The	anthracyclines	
are	associated	with	Type	1	cardiotoxicity,	meaning	that	the	damage	induced	on	the	
heart	is	irreversible	and	often	leads	to	heart	failure.	The	monoclonal	antibodies	are	
associated	with	Type	2	cardiotoxicity,	meaning	that	the	damage	induced	is	typically	
reversible	and	that	it	is	not	dose	dependent.	This	kind	of	damage	is	typically	
repaired	upon	completion	of	chemotherapy	treatment	and	possibly	going	on	heart	
medications.	With	that	being	said,	depending	on	the	specific	chemotherapy	used,	it	
can	be	given	in	a	situation	where	a	type	2	chemotherapy	induces	type	1	effects,	such	
that	a	monoclonal	antibody	is	given	with	or	too	soon	after	anthracycline	treatment.	
The	goal	of	this	thesis	is	to	examine	one	of	each	of	the	above	classes	of	
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chemotherapeutic	drugs.	The	mechanism	of	action	and	the	effects	on	the	heart	are	
discussed	in	detail.	
Keywords	and	phrases:	chemotherapy,	cardiotoxicity,	anthracyclines,	dexrazoxane,	
taxanes,	monoclonal	antibodies,	alkylating	agents,	tyrosine	kinases,	antiestrogens
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Tables	
Table	1	
Chemotherapy	Drug	Details	
Chemotherapy	 Side	Effects	 Class	 Method	
of	
Dosage	
How	
often?	
Lapatinib	
(Tykerb)	
Liver	damage,	
shortness	of	
breath,	
heartburn,	
fast	or	
irregular	
heart	beat		
Kinase	
Inhibitors	
Oral	 1/day	
Trastuzumab	 Heartburn,	
Short	of	Air,	
Fast/irregular	
heart	beat	
Monoclonal	
antibodies	
Liquid	IV	 1/week		
Cyclophosphamide	 Difficulty	
breathing,	
SOB,	chest	
pain	
Alkylating	
agents	
Injected	
Powder	
Depends	
Docetaxel	 Extreme	
tiredness,	
stomach	pain	
Taxanes	 Liquid	IV	 3	weeks	
Doxorubicin	
Hydrochloride	
Heart	
problems	
Anthracyclines	 Liquid	IV	 1x	every	
21-28	
days	
Tamoxifen	Citrate	 Coughing	up	
blood,	SOB	
Antiestrogens	 Oral	 Twice	a	
day	
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According	to	the	World	Health	Organization,	cancer	killed	9.6	million	people	
worldwide	in	2018,	and	in	2010,	the	total	cost	of	cancer	was	around	1.16	trillion	
dollars	(2018).	Cancer	is	a	disease	that	is	characterized	by	cells	continually	dividing	
in	the	body	without	control.	Chemotherapies	are	drugs	used	to	disrupt	this	process	
and	restart	the	body’s	normal	process	of	creating	cells	as	needed	and	killing	those	
cells	that	are	damaged	and/or	are	old.	The	primary	objective	of	chemotherapy	is	to	
“impair	mitotic	and	metabolic	process	of	cancer	cells”;	however,	these	drugs	are	so	
potent,	that	they	do	not	only	destroy	those	cells,	but	healthy	cells,	as	well	
(Angsutararux,	Luanpitpong,	and	Issaragrisil,	2015).	Chemotherapies	are	an	
essential	part	of	the	treatment	for	cancer,	and	although	it	saves	many	people	from	
the	horrible	fate	of	cancer,	it	has	its	known	side	effects	that	can	cause	many	long-
standing	issues	alone.	
Within	the	last	50	years,	there	have	been	many	studies	performed	on	those	
who	have	had	chemotherapies	in	their	past.	It	is	now	known	that	although	these	
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drugs	are	wonderful	for	the	treatment	of	cancer,	it	is	detrimental	to	heart	function.	
According	to	the	National	Cancer	Institute,	the	toxic	effects	on	the	heart,	known	as	
cardiotoxicity,	were	first	identified	in	the	1960s.	The	different	types	of	
cardiotoxicity	identified	were	acute,	subacute,	and	chronic	(Mihalcea,	Florescu,	&	
Vinereanu,	2017).	Acute	cardiotoxicity	is	toxicity	that	occurs	within	2	weeks	of	
starting	the	treatment	while	subacute	cardiotoxicity	occurs	after	2	weeks	of	starting	
the	treatment	(Mihalcea,	Florescu,	&	Vinereanu,	2017).	Chronic	cardiotoxicity	
occurs	either	within	1	year	or	after	1	year,	which	typically	leads	to	heart	failure	and	
death	(Mihalcea,	Florescu,	&	Vinereanu,	2017).		
Depending	on	the	type	of	chemotherapy	and	the	duration	of	treatment,	the	
effects	on	the	heart	are	widely	varied.	For	example,	some	classes	of	chemotherapy	
may	cause	a	temporary	irregular	heartbeat	whereas	other	therapies	may	lead	to	
myocyte	vacuole	degeneration,	which	is	injury	to	the	cardiac	muscle	cells.	
(Angsutararux,	Luanpitpong,	and	Issaragrisil,	2015).	Because	it	is	known	that	
chemotherapies	do	have	an	effect	on	the	heart,	there	have	been	multiple	studies	
performed	to	determine	how	to	treat	and/or	prevent	chemotherapy-induced	
cardiotoxicity.	Those	who	fight	the	long	battle	of	cancer	deserve	a	better	treatment	
option	that	is	not	only	effective	in	fighting	cancer,	but	also	comes	without	the	
lifelong	and	potentially	irreversible	damage	to	the	heart.	
	 Cancer	is	a	disease,	and	like	any	other	disease,	there	are	multiple	drugs	that	
can	attempt	to	rid	the	body	of	the	destructive	cells.	There	are	different	classes	of	
chemotherapies	ranging	from	the	anthracyclines	to	the	monoclonal	antibodies.	
Because	there	are	so	many	different	classes	and	specific	drugs	approved	for	the	use	
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of	all	cancers,	only	those	that	are	approved	for	the	use	of	breast	cancer	will	be	
considered.	According	to	the	World	Health	Organization,	breast	cancer	tied	with	
lung	cancer	for	the	number	of	cases	in	2018,	which	was	2.09	million	each	
worldwide;	moreover,	breast	cancer	is	also	in	the	top	5	for	cancer	deaths	at	627,000	
deaths	in	the	world	(2018).	According	to	the	National	Cancer	Institute,	there	are	
about	69	chemotherapies	that	have	been	approved	to	treat	those	with	breast	cancer,	
and	many	of	those	are	in	different	chemotherapy	classes,	meaning	that	the	drugs	
have	different	mechanisms	of	actions	and	levels	of	potency	(2019).	There	are	many	
different	types	of	breast	cancer,	with	one	of	those	being	HER2-positive	breast	
cancer.	This	kind	of	breast	cancer	has	a	protein	known	as	human	epidermal	growth	
factor	receptor	2	(HER2)	that	fosters	the	growth	of	cancer	cells;	furthermore,	these	
kinds	of	cancers	are	inclined	to	be	more	aggressive	than	any	other	type	of	breast	
cancer	(Mayo	Clinic,	2020).	Some	other	types	of	breast	cancer	include	
angiosarcomas,	which	is	less	than	1%	of	breast	cancers;	inflammatory	breast	cancer,	
which	is	between	1-5%	of	breast	cancers;	and	triple-negative	breast	cancer,	which	is	
about	15%	of	breast	cancers	(American	Cancer	Society,	2019).	The	chemotherapy	
classes	that	will	be	discussed	include	anthracyclines,	monoclonal	antibodies,	
taxanes,	alkylating	agents,	and	kinase	inhibitors.	For	each	of	the	classes	of	common	
chemotherapies,	the	mechanism	of	action	in	the	body,	and	its	toxic	effects	on	the	
heart	will	be	discussed.	
	 When	discussing	cardiotoxicity,	the	classes	and	individual	drugs	are	divided	
into	Type	I	and	Type	II	chemotherapies.	Type	I	chemotherapies	are	those	drugs	that	
predominantly	cause	irreversible	damage	due	to	cell	loss	resulting	in	
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pathophysiology,	or	injury,	of	the	heart;	however,	Type	II	chemotherapies	are	those	
drugs	that	predominantly	cause	reversible	damage	due	to	alterations	in	the	
mitochondria	and	proteins	in	the	heart	(Curigliano,	et	al.,	2012).	With	Type	II	
chemotherapies,	often	patients	can	return	to	normal	cardiovascular	function	with	
time;	whereas,	Type	I	chemotherapies	can	induce	progressive	cardiovascular	
disease	(Curigliano,	et	al.,	2012).		These	classifications	are	based	on	what	generally	
occurs	with	the	use	of	the	specific	chemotherapy.	However,	there	are	exceptions	
where	a	drug	may	be	classified	as	Type	II	chemotherapy	but	when	presented	in	the	
right	circumstances	can	trigger	Type	I-like	effects.	The	severity	of	the	cardiotoxicity	
is	also	determined	by	the	route	of	administration	of	the	chemotherapy,	the	dosage	
course,	and	the	duration	of	the	treatment	(Angsutararux,	Luanpitpong,	and		
Issaragrisil,	2015).	As	seen	in	Table	1,	all	of	the	drugs	in	the	classes	discussed	in	this	
paper	can	cause	some	serious	side	effects;	however,	not	all	of	them	are	associated	
with	the	cardiotoxic	effects	in	which	some	of	the	classes	are	known.	The	differences	
in	these	chemotherapies	(their	mechanisms	and	effects)	and	their	classes	will	be	
examined	in	the	entirety	of	this	paper.	
	
Anthracyclines	
	 The	class	of	chemotherapies	known	as	the	anthracyclines	is	very	widely	used	
for	many	different	malignancies,	but	is	most	often	used	to	treat	breast	cancer.	
Doxorubicin	is	a	first-line	treatment	and	is	used	to	treat	32%	of	those	with	breast	
cancer	(McGowan	et	al.,	2017).	However,	the	anthracyclines	as	a	whole	are	
considered	to	be	a	Type	I	chemotherapy	and	are	considered	to	give	rise	to	heart	
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defects	that	are	more	common	and	detrimental	than	other	chemotherapy	classes	
(Angsutararux,	Luanpitpong,	and	Issaragrisil,	2015).	Because	of	the	wide	range	of	
effects	that	the	anthracyclines	can	impose,	the	effects	are	divided	into	acute	and	
chronic.	Acute	effects	are	those	that	occur	directly	after	or	during	the	course	of	the	
treatment	and	are	typically	reversible;	whereas,	the	chronic	effects	are	those	that	
can	occur	years	after	the	treatment	and	are	frequently	more	detrimental	to	the	
heart	(Angsutararux,	Luanpitpong,	and	Issaragrisil,	2015).	Risk	factors	in	
developing	cardiotoxicity	following	anthracycline	treatment	include	age	(those	
younger	than	18	and	older	than	65	are	at	a	greater	risk),	pre-existing	conditions,	
and	renal	failure;	hence,	those	that	have	a	greater	number	of	risk	factors,	have	an	
even	greater	chance	of	developing	congestive	heart	failure	following	treatment	
(Zamorano,	et	al.,	2016).	
The	anthracyclines	are	drugs	that	target	the	Topoisomerase-alpha	enzyme	in	
cancer	cells	that	exhibit	an	extreme	division	cycle	(Tadic,	Cuspidi,	Hering,	Venneri,	&	
Danylenko,	2017).	In	a	healthy	cell,	the	topoisomerases	produce	protective	effects	
on	the	cell.	Topoisomerase-2𝛽	is	found	largely	in	cardiomyocytes,	cells	making	up	
the	heart	muscle,	thus	causing	damage	to	the	heart	when	harmed.	However,	
doxorubicin	binds	to	the	Topoisomerase-2𝛽	enzyme	and	lowers	its	ability	to	protect	
against	DNA	replication	normally	(Swiger,	Singh,	&	Lenihan	2017).	Topoisomerase-
𝛼	is	structurally	identical	to	Topoisomerase-2𝛽,	so	anthracyclines	affect	both	
leading	to	anthracycline-induced	cardiomyopathy	(Tadic,	Cuspidi,	Vasic,	&	Kerkhof,	
2018).	This	isoenzyme,	Topoisomerase-𝛼,	binds	to	doxorubicin	and	triggers	
mitochondrial	dysfunction	(McGowan	et	al.,	2017).		
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During	mitochondrial	DNA	recombination,	Topoisomerase-2𝛽	controls	the	
chromatin	relaxation	and	condension,	while	also	promoting	the	rearrangement	of	
genes	(Goffart,	Hangas,	&	Pohjoismäki,	2019).	The	mitochondrial	DNA	in	mammals	
is	usually	in	the	shape	of	a	circle,	but	can	be	relaxed	or	coiled	tightly;	nevertheless,	
the	mitochondrial	DNA	in	cardiomyocytes	are	much	more	complex	in	that	they	form	
networks	with	other	mitochondria	(Goffart,	Hangas,	&	Pohjoismäki,	2019).	Because	
of	this,	Topoisomerase-2𝛽,	as	well	as	other	subunits	of	topoisomerase,	is	needed	to	
relax	the	coiling	during	the	DNA	replication	and	transcription	(Goffart,	Hangas,	&	
Pohjoismäki,	2019).	Anthracyclines	inhibit	Topoisomerase-2𝛽	causing	the	DNA	to	
stay	coiled	tightly;	similarly,	there	has	also	been	evidence	of	changes	in	the	
structure	of	mitochondrial	DNA	attributable	to	the	breaks	in	the	double	strands	of	
DNA	that	presents	with	topoisomerase	poisoning	(Goffart,	Hangas,	&	Pohjoismäki,	
2019).		
The	mitochondria	in	cardiomyocytes	generate	reactive	oxygen	species	
through	the	electron	transport	chain	(Siasos	et	al.,	2018).	Doxorubicin-induced	
cardiotoxicity	may	be	caused	by	a	multitude	of	effects	including	damage	to	the	
mitochondria,	apoptosis,	and	an	increase	in	oxidative	stress	(Potočnik,	et	al.,	2017).	
Anthracyclines	in	general	are	known	to	invoke	intracellular	damage	due	to	the	
production	of	hydroxyl	radicals	that	are	tremendously	toxic	to	the	body;	
correspondingly,	these	are	made	by	the	production	of	highly	reactive	oxygen	species	
(oxygen	species	reacting	with	iron),	which	are	exacerbated	with	anthracycline	
treatment	(Tadic,	Cuspidi,	Vasic,	&	Kerkhof,	2018).	This	oxygen	species	leads	to	an	
increase	in	apoptosis	and	deterioration.	Anthracyclines,	in	general,	evoke	harm	on	
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the	mitochondria	and	Topoisomerase-2𝛽,	which	leads	to	a	plethora	of	other	damage	
and	can	ultimately	lead	to	heart	failure.	
The	peroxisome	proliferator-activated	receptor	(PPAR)	regulates	oxidative	
metabolism,	which	also	occurs	in	the	mitochondria	(McGowan	et	al.,	2017).	This	
receptor	is	activated	by	a	ligand	binding	to	the	active	site,	causing	the	receptor	to	
undergo	a	conformational	change	that	ultimately	regulates	gene	transcription	(Lee	
&	Kim,	2015).	The	receptor	is	found	in	3	different	subtypes	in	the	body:	alpha,	
gamma,	and	beta	(Tyagi,	et	al.,	2011).	The	alpha,	𝛼,	subunit	allows	for	energy	to	be	
generated	for	the	heart	muscle	and	other	areas	of	the	body	in	playing	a	crucial	role	
in	the	breakdown	of	fatty	acid	molecules	in	the	liver	(Tyagi,	et	al.,	2011).	The	
gamma,	𝛾,	subunit	acts	as	a	receptor	and	regulates	fatty	acid	storage	(Tyagi,	et	al.,	
2011).	A	study	using	PPAR-gamma	knockout	mice,	which	“exhibit	progressive	
cardiac	fibrosis	with	abnormal	mitochondria	and	myofibrils,”	has	demonstrated	that	
this	isoform	of	PPAR	is	crucial	in	the	protection	of	cardiomyocytes	(Lee	&	Kim,	
2015).	Lastly,	the	beta,	𝛽,	subunit,	promotes	fatty	acid	metabolism;	however,	it	has	
also	been	demonstrated	that	the	ligand	could	potentially	inhibit	cardiac	
hypertrophy	(Tyagi,	et	al.,	2011).	One	study	of	cardiomyocytes	taken	from	mice	
showed	that	doxorubicin	significantly	decreased	the	amount	of	the	PPAR-beta	
receptor.		As	PPAR	is	protective,	cells	that	exhibit	a	decrease	in	receptor	number	
will	lose	the	ability	to	effectively	protect	against	cardiac	hypertrophy	as	the	cells	
have	become	desensitized	(Chen,	Chen,	&	Cheng,	2013).	Having	too	much	or	too	
little	of	the	PPAR,	however,	could	potentially	foster	cardiomyopathy	or	further	
myocardial	damage	(Lee	&	Kim,	2015).	
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Anthracyclines	are	transformed	from	a	quinone	form	to	a	semiquinone	form	
(one	electron	reduction	form)	by	enzymes	in	the	mitochondria	(Angsutararux,	
Luanpitpong,	&	Issaragrisil,	2015).	Furthermore,	the	formation	of	the	semiquinone	
form	of	the	anthracycline	(in	the	body)	reacts	promptly	when	in	contact	with	
oxygen;	likewise,	when	it	reacts	with	the	oxygen,	a	superoxide	anion	is	formed	along	
with	a	hydrogen	peroxide,	which	then	leads	to	an	increase	in	the	number	of	reactive	
oxygen	species	(Edwardson.	et	al.,	2015).	As	discussed	previously,	an	increase	in	the	
number	of	reactive	oxygen	species	would	increase	the	rate	of	apoptosis	in	cells	
(Siasos	et	al.,	2018).	This	process	has	been	discovered	to	occur	in	the	mitochondria,	
cytoplasm,	and	sarcoplasmic	reticulum	and	create	toxic	aldehydes	that	escape	the	
cells	(Edwardson,	et	al.,	2015).	For	the	heart,	however,	the	semiquinone	form	of	the	
anthracycline	is	more	associated	with	the	dysfunction	that	the	form	induces	to	the	
mitochondria;	moreover,	the	heart	needs	adenosine	triphosphate	(ATP)	to	pump	
blood	throughout	the	body	and	any	damage	to	the	mitochondria	would	impair	that	
process	(Edwardson,	et	al.,	2015).	According	to	Edwardson,	D.W.,	cardiomyocytes	
acquire	about	90%	of	their	ATP	from	the	mitochondria	(2015).	The	formation	of	the	
semiquinone	form	of	an	anthracycline	inducing	damage	on	the	mitochondria	in	
cardiomyocytes	reduces	the	ATP	that	is	formed	and	ultimately	impairs	the	heart’s	
ability	to	pump	blood	throughout	the	body.	
Anthracyclines	can	also	go	through	the	reduction	of	two	electrons	when	in	
the	body,	and	the	product,	secondary	alcohol	metabolites,	have	been	suggested	to	be	
a	potential	factor	in	cardiotoxicity	induced	by	anthracyclines	(Edwardson,	et	al.,	
2015).	However,	the	products	(hydroxylated	anthracyclines)	only	inflict	a	greater	
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amount	of	cardiotoxicity	than	the	parent	compounds	due	to	their	ability	to	collect	in	
the	tissue	of	the	heart;	moreover,	the	products	collect	a	significant	amount	more	in	
the	heart	than	anywhere	else	in	the	body	(Edwardson,	et	al.,	2015).	The	reasoning	
behind	why	the	products	accumulate	more	in	the	heart	is	unknown	(Edwardson,	et	
al.,	2015).	However,	the	consequence	of	hydroxylated	anthracyclines	building	up	in	
the	heart	is	the	onset	of	cardiomyopathy;	furthermore,	this	could	occur	at	any	time	
between	the	beginning	of	the	treatment	to	months	later	(Edwardson,	et	al.,	2015).	
Doxorubicin	is	an	especially	prevalent	and	effective	anthracycline	that	is	
used	to	treat	a	variety	of	different	cancers.	However,	the	drug	is	known	for	its	
extremely	damaging	effects	on	the	heart.	According	to	Angsutararux,	Luanpitpong,	
and	Issaragrisil,	the	cumulative	amount	of	doxorubicin	that	is	given	is	crucial	to	the	
likelihood	of	succumbing	to	heart	failure	following	treatment,	as	exceeding	
550𝑚𝑔/𝑚)	considerably	increases	the	chances	of	ending	up	with	congestive	heart	
failure	from	4%	to	18%		(2015).	Similarly,	the	risk	jumps	up	to	a	48%	chance	when	
receiving	700𝑚𝑔/𝑚)	(Zamorano,	et	al.,	2016).		
Moreover,	one	study	demonstrated	that	the	use	of	doxorubicin	over	a	6-week	
time	frame	almost	completely	rids	the	body	of	cardiac-resident	stem	and	progenitor	
cells	in	the	myocardium,	both	of	which	are	stem	cells	that	commit	to	becoming	
cardiomyocytes	(Madonna,	et	al.,	2017).	Doxorubicin	and	other	anthracyclines	have	
harmful	effects	on	both	the	cardiomyocytes	and	the	stem	cells	that	commit	to	
becoming	cardiomyocytes.	Without	these	stem	cells,	the	damage	becomes	
irreversible	and	no	new	cells	can	be	produced.				
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Monoclonal	Antibodies	
	 Monoclonal	antibodies	are	another	class	of	chemotherapies	that	is	widely	
used	in	the	treatment	of	many	cancers,	including	breast	cancer.	These	immune	
system	proteins	are	made	in	the	lab	to	act	like	the	body’s	antibodies	and	
acknowledge	specific	targets	(National	Cancer	Institute,	2019).	The	proteins	can	
only	bind	to	one	substance	each,	with	one	of	those	being	cancer	cells	(National	
Cancer	Institute,	2019).	Monoclonal	antibodies	can	be	used	alone	or	with	other	
chemotherapeutic	agents	in	order	to	carry	substances	directly	to	the	cancer	cells	
(National	Cancer	Institute,	2019).	Some	monoclonal	antibodies	target	the	immune	
system,	turning	it	against	the	cancer	cells,	while	also	binding	to	the	cancer	cells	in	
order	to	help	the	immune	system	kill	the	cancer	cells	(National	Cancer	Institute,	
2019).	Monoclonal	antibodies	were	not	originally	meant	for	chronic	therapy,	but	
later	on	more	human-like	monoclonal	antibodies	were	developed		(Shepard,	et	al.,	
2017).		
Monoclonal	antibodies	are	Type	2	chemotherapies	because	the	effects	on	the	
heart	are	not	dose-dependent	and	the	damage	they	can	cause	to	the	heart	is	
normally	reversible	(Tadic,	Cuspidi,	Hering,	Venneri,	&	Danylenko,	2017).	However,	
monoclonal	antibodies	can	contribute	to	the	progression	of	a	tumor	similar	to	other	
immunosuppressant	drugs	and	cause	cardiotoxicity	(Singh,	et	al.,	2018).	The	first	
monoclonal	antibody	was	approved	by	the	FDA	for	cancer	treatment	(specifically	
lowgrade	B	cell	lymphoma)	in	1997;	likewise,	there	are	now	over	60	different	
monoclonal	antibodies	that	the	FDA	has	approved	(Singh,	et	al.,	2018).		
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	 A	common	monoclonal	antibody	used	in	the	treatment	of	breast	cancer	is	
trastuzumab	(Tadic,	Cuspidi,	Vasic,	&	Kerkhof,	2018).	The	tyrosine-protein	kinase	
expressed	on	cancer	cells	is	inhibited	by	trastuzumab;	however,	cardiomyocytes	
express	the	same	kinase	and	when	inhibited,	dilated	cardiomyopathy	is	evoked,	
which	is	blood	pumping	less	effectively	through	the	heart	due	to	the	expansion,	or	
dilation,	of	the	left	ventricle	(Tadic,	Cuspidi,	Vasic,	&	Kerkhof,	2018).	The	human	
epidermal	growth	factor	receptor	type	2	that	trastuzumab	inhibits,	regulates	growth	
and	survival	of	cardiomyocytes	and	other	cells	(Higgins,	O’Halloran,	&	Chang,	2015).	
The	chemotherapy	has	also	been	linked	to	the	inhibition	of	the	neuregulin-1,	which	
normally	activates	the	human	epidermal	growth	factor	receptor	type	2	on	
cardiomyocytes	as	a	protective	mechanism	(Nicolazzi,	et	al.,	2018).	This	inhibition,	
though,	causes	the	inability	of	the	cardiomyocyte	to	maintain	sarcomeres	(allows	
the	lower	chambers	of	the	heart	muscle	to	contract	in	unison	and	the	upper	
chambers	of	the	heart	to	contract	in	unison)	and	subproducts	of	ATP	formation.	
Moreover,	this	leads	to	oxidative	stress	and	the	upregulation	of	angiotensin	II,	which	
prevents	neuregulin-1	from	binding	to	other	receptors	to	make	up	for	the	blockage	
of	the	human	epidermal	growth	factor	receptor	type	2	and	also	induces	apoptosis	
(Nicolazzi,	et	al.,	2018).	This,	in	turn,	leads	to	greater	oxidative	stress.	Trastuzumab	
blocks	all	of	the	possible	ways	for	the	cardiomyocytes	to	repair	themselves	and	
regulate	their	survival,	therefore,	damaging	the	heart	(but	not	to	the	point	of	no	
return).	After	discontinuing	treatment,	the	heart	will	be	able	to	work	back	up	to	
regulating	the	cardiomyocytes	and	the	sarcomeres	and	making	any	repairs	that	will	
need	to	be	made	to	the	heart.	
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Because	this	kinase	receptor	regulates	survival	of	the	cardiomyocytes,	when	
it	is	inhibited,	the	cardiomyocytes’	ability	to	repair	itself	and	respond	to	stress	and	
injury	are	also	compromised	(Higgins,	O’Halloran,	&	Chang,	2015).	According	to	
Higgins,	O’Halloran,	and	Chang,	after	discontinuing	the	chemotherapy,	the	patients	
in	a	study	all	recovered,	with	16%	being	spontaneous	and	84%	being	with	heart	
failure	treatment	(2015).	With	that	being	said,	if	trastuzumab	is	given	with	
anthracycline	treatment	or	given	too	soon	after	anthracycline	treatment,	the	
damage	can	become	permanent,	making	it,	in	this	instance,	a	type	1	chemotherapy	
that	can	lead	to	the	development	of	congestive	heart	failure	(Higgins,	O’Halloran,	&	
Chang,	2015).	Because	trastuzumab	prevents	the	heart	from	repairing	itself,	the	
cardiomyocytes	will	not	be	able	to	repair	some	of	the	damage	induced	by	the	
anthracyclines	if	it	is	introduced	too	soon	after	anthracycline	treatment.	The	
damage	induced	by	the	anthracyclines	will	then	be	built	on	by	the	“reversible”	
damage	of	trastuzumab;	however,	with	damage	already	being	done,	the	
trastuzumab	damage	will	become	permanent.	Other	factors	that	will	put	patients	at	
an	increased	risk	of	cardiotoxicity	include	smoking,	diabetes,	hypertension,	age	
(older	than	49	years	old),	a	decreased	left	ventricular	ejection	fraction,	or	any	
preexisting	cardiac	diseases	(Higgins,	O’Halloran,	&	Chang,	2015).		
In	patients	treated	only	with	trastuzumab,	and	not	anthracyclines	before	or	
during	trastuzumab	treatment,	the	incident	of	cardiomyopathy	is	much	lower;	
furthermore,	there	is	no	difference	in	the	thickness	of	the	right	and	left	ventricle	
walls	in	a	study	on	mice	who	were	only	treated	with	trastuzumab	(Tadic,	Cuspidi,	
Hering,	Venneri,	&	Danylenko,	2017).	This	suggests	that	treatment	with	
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trastuzumab,	when	used	to	treat	cancer,	prevents	the	changes	that	anthracyclines	
typically	induce	and	has	some	cardioprotective	effects	while	also	fighting	the	cancer	
cells;	however,	it	can	cause	some	reversible	damage	of	its	own.	Trastuzumab-
induced	left-ventricular	contractile	dysfunction	occurs	at	a	rate	of	around	3%	when	
given	without	other	chemotherapies	(most	common);	whereas,	the	risk	of	heart	
failure	to	patients	treated	with	trastuzumab	according	to	a	study	of	11,000	patients	
was	2.5%	(Higgins,	O’Halloran,	&	Chang,	2015).	Trastuzumab	in	breast	cancer	has	
led	to	a	50%	decrease	in	the	cancer	returning	and	has	also	improved	the	survival	
rate	to	33%	of	those	treated	with	trastuzumab	(Curigliano,	et	al.,	2012).	In	an	11-
year	study	of	patients	treated	with	trastuzumab	after	another	chemotherapy	
(anthracyclines	and/or	taxanes)	in	the	treatment	of	breast	cancer,	the	observation	
group	had	63%	of	patients	with	10	years	free	of	disease;	however,	there	was	69%	of	
patients	with	10-year	survival	and	no	diseases	for	both	the	group	treated	with	1	
year	of	trastuzumab	and	2	years	of	trastuzumab	(Cameron,	Piccart-Gebhart,	&	
Gelber,	2017).	Therefore,	there	is	a	significant	improvement	in	the	disease	outcome.		
However,	in	one	study,	elevation	of	the	right	ventricle	filling	pressure	
signified	a	decrease	in	the	diastolic	function	of	the	right	ventricle	of	the	heart	(Tadic,	
Cuspidi,	Hering,	Venneri,	&	Danylenko,	2017).	In	another	study	of	9	female	breast	
cancer	patients,	it	was	discovered	that	after	6	months	of	trastuzumab	therapy,	the	
circumferential	strain	on	the	right	ventricle	decreased,	but	the	systolic	function	of	
the	right	ventricle	was	normal	(Tadic,	Cuspidi,	Hering,	Venneri,	&	Danylenko,	2017).	
Circumferential	strain	is	a	measure	of	the	reduction	of	the	diameter	of	the	
ventricles,	and	thus,	a	measure	of	cardiac	dysfunction	(Støylen,	2018).	Overall,	
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trastuzumab	is	a	safer	treatment	option	for	cancers	because	the	damage	it	induces	is	
typically	reversible,	unless	it	used	in	combination	with	anthracyclines,	and	it	has	
demonstrated	an	increase	in	the	survival	rate	of	those	with	breast	cancer.	
	
Taxanes	
	 The	taxanes,	discovered	in	the	1960s,	are	a	chemotherapeutic	class	that	is	
most	often	used	in	the	treatment	of	breast	cancer,	as	it	is	one	of	the	most	effective	in	
treating	the	cancer	(Gradishar,	2012).	It	was	first	used	for	humans	in	the	1990s,	
specifically	for	metastatic	breast	cancer,	because	in	doing	clinical	trials,	there	was	
hope	that	it	would	have	improved	outcomes	in	both	early	and	late	stage	cancer	
(Gradishar,	2012).	Compared	to	other	chemotherapy	regimens,	the	patient	survival	
rate	when	treated	with	taxanes	versus	other	chemotherapeutic	agents	is	higher;	
furthermore,	the	survival	rate	of	those	with	metastatic	breast	cancer	between	1991	
and	1995	was	only	34%,	but	between	1997	and	2001,	the	survival	rate	had	
increased	to	45%	at	2	years	(Ho	&	Mackey,	2014).	As	of	2016,	all	of	the	taxane	drugs	
are	FDA	approved	to	be	administered	intravenously	(Ojima,	Lichtenthal,	Lee,	Wang,	
&	Wang,	2016).	
	 The	taxane	chemotherapeutic	class	promotes	both	bradyarrhythmias	and	
tachyarrhythmias,	which	both	can	lead	to	heart	failure	(Lage,	et	al.,	2019).	The	
cardiotoxic	risks	of	taking	taxanes	are	not	quite	known	(Zamorano,	et	al.,	2016).	It	is	
known,	however,	that	the	taxanes	can	activate	apoptotic	pathways	(Lage,	et	al.,	
2019).	Furthermore,	taxanes	prevent	the	mitotic	spindle	from	going	through	
depolymerization	by	stabilizing	the	microtubules	𝛽-tubulin	subunit	(Lage,	et	al.,	
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2019).	This	causes	cell	cycle	arrest	in	both	the	G2	and	Mitosis	phases	of	the	cell	
cycle,	which	then	causes	cell	death	(Gradishar,	2012).	The	cell	is	not	able	to	go	
through	mitosis	because	the	microtubules	are	not	able	to	pull	the	chromosomes	to	
the	opposite	side	of	the	cell	to	go	through	with	cytokinesis,	so	the	cell	activates	
apoptosis.	
	 Docetaxel	is	a	derivative	of	paclitaxel	(the	original	taxane	discovered	in	the	
1960s)	that	is	more	potent	(Gradishar,	2012).	It	was	discovered	in	the	1980s,	and	
received	Food	and	Drug	Administration	(FDA)	approval	in	1996	for	the	treatment	of	
breast	cancer	that	has	returned	for	at	least	the	2nd	time	(Gradishar,	2012).	Docetaxel	
is	a	chemotherapeutic	agent	that	is	used	in	the	treatment	of	many	cancers,	including	
breast	cancer	and	lung	cancer.	Some	toxicities	induced	by	docetaxel	include	edema	
(swelling)	and	shortness	of	breath	(Ojima,	et	al.,	2016).	The	chemotherapy	often	
comes	with	acute	infusion	reactions,	which	means	that	the	symptoms	occur	within	
minutes	or	hours	of	receiving	the	dose	of	docetaxel;	moreover,	these	symptoms	
include	fever,	hypoxia	(low	oxygen	in	the	blood),	dyspnea	(difficulty	breathing),	
cardiorespiratory	arrest	and	anaphylaxis	(Ho	&	Mackey,	2014).	
Docetaxel	treatment	increases	the	activity	of	NADPH	oxidases,	which	is	the	
source	of	most	of	our	oxygen	production;	furthermore,	this	results	in	an	increase	in	
reactive	oxygen	species	(Lage,	et	al.,	2019).	An	increase	in	the	reactive	oxygen	
species	decreases	the	amount	of	ATP	produced,	and	then	increases	the	rate	of	
apoptosis,	which	ultimately	leads	to	damage	of	the	heart	(Siasos	et	al.,	2018).	
	 Heart	failure	induced	by	the	use	of	paclitaxel	and	docetaxel	in	patients	is	
anywhere	from	2.3-8%	of	patients	(Min	&	Wierzbicki,	2017).	LVEF,	left	ventricular	
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ejection	fraction,	reductions	of	at	least	15%	have	presented	in	6-8%	of	patients	
(Madeddu,	et	al.,	2016).	There	have	also	been	cases	of	myocardial	ischemia	(blocked	
blood	flow	to	the	heart)	in	those	treated	with	either	paclitaxel	or	docetaxel	(Min	&	
Wierzbicki,	2017).	Docetaxel	stabilizes	microtubules,	and	may	therefore,	cause	
contractile	dysfunction;	furthermore,	left	ventricular	diastolic	dysfunction	has	been	
determined	to	be	induced	by	docetaxel	(Shimoyama,	et	al.,	2001).	One	of	the	known	
causes	of	congestive	heart	failure	is	diastolic	dysfunction	(Shimoyama,	et	al.,	2001).	
If	docetaxel	induces	left	ventricular	diastolic	dysfunction,	the	risk	of	developing	
congestive	heart	failure	is	going	to	increase	with	the	use	of	docetaxel.	
	 A	62-year-old	Hispanic	man	was	diagnosed	with	metastatic	prostate	cancer	
and	was	being	treated	with	docetaxel	(Huq,	Balvanz,	&	Mambourg,	2018).	Within	15	
minutes	of	the	2nd	cycle	of	chemotherapy	being	infused,	the	patient	developed	a	
stable,	but	chronic,	atrial	fibrillation	(Huq,	Balvanz,	&	Mambourg,	2018).	The	patient	
abided	by	the	physican’s	recommendation	of	using	corticosteroids	before	the	
chemotherapy,	but	still	ended	up	developing	atrial	fibrillation	(Huq,	Balvanz,	&	
Mambourg,	2018).	There	is	less	cardiac	toxicity	with	the	use	of	docetaxel	than	there	
is	with	paclitaxel,	but	the	risk	for	heart	damage	is	still	there	when	using	docetaxel	
because	everyone	is	going	to	react	differently	to	medications,	especially	those	that	
can	have	very	severe	side	effects,	like	congestive	heart	failure.	Docetaxel	seems	to	be	
better	for	the	treatment	of	breast	cancer	compared	to	the	anthracyclines	because	it	
has	been	demonstrated	to	increase	the	survival	rate	of	those	with	cancer	while	also	
lessening	the	cardiotoxic	effects	on	the	heart;	moreover,	the	drug	was	first	used,	
specifically,	for	the	treatment	of	metastatic	breast	cancer.		
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Alkylating	Agents	
	 Alkylating	Agents	are	found	both	in	the	environment	and	in	cells,	as	they	are	
in	pollutants	such	as	tobacco	smoke	and	are	also	byproducts	in	the	body	(Fu,	Calvo,	
&	Samson,	2012).	These	agents	are	dangerous	to	human	health	because	of	their	
effects,	which	include	cytotoxicity,	carcinogenic	effects,	and	teratogenic	effects;	in	
spite	of	this,	the	agents	are	used	as	a	chemotherapy	to	kill	cancer	cells	(Fu,	Calvo,	&	
Samson,	2012).	The	alkylating	agents	are	the	oldest	class	of	chemotherapies	(Han,	
Zhou,	&	Liu,	2017).	The	United	States	released	mustard	gas,	an	alkylating	agent,	
against	the	Germans	in	World	War	2	(1943),	which	caused	a	major	reduction	in	the	
number	of	white	blood	cells;	furthermore,	this	led	to	the	study	of	them	as	an	
anticancer	agent	(Iqubal,	et	al.,	2019).	They	act	on	cancer	cells	by	adding	alkyl	
groups	to	the	DNA;	thus,	the	two	strands	of	DNA	are	then	cross-linked	and	
prevented	from	replicating	(Higgins,	O’Halloran,	&	Chang,	2015).	Risk	factors	
associated	with	alkylating	agents-induced	cardiotoxicity	include	old	age,	
combination	therapy,	and	total	single	dose	(Han,	Zhou,	&	Liu,	2017).	
	 DNA	damage	is	induced	when	the	alkylating	agents	react	with	DNA	bases	(Fu,	
Calvo,	&	Samson,	2012).	When	a	certain	alkylating	agent	is	introduced	to	the	body,	
the	guanine	at	the	N7-position	on	DNA,	which	has	a	high	nucleophilic	reactivity,	is	
typically	used	to	form	N7-methyl	guanine,	a	predominant	methylation	adduct	
(Figure	1);	moreover,	DNA	alkylation	lesions	are	formed	and	N7-methyl	guanine	is	
responsible	for	60-80%	of	them	(Fu,	Calvo,	&	Samson,	2012).	N7-methyl	guanine	
itself	is	not	cytotoxic,	but	it	forms	apurinic	or	apyrimidinic	(AP)	sites,	which	are	
places	in	the	DNA	where	a	purine	or	pyrimidine	is	not	present	on	one	side	of	the	
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double	helix;	furthermore,	these	sites	are	toxic	(Fu,	Calvo,	&	Samson,	2012).	These	
base	adducts	can	induce	mutagenesis	and/or	inhibit	the	replication	and	
transcription	of	DNA,	which	leads	to	cell	death	in	both	healthy	cells	and	cancer	cells	
(Fu,	Calvo,	&	Samson,	2012).	
	 A	well-known	alkylating	agent	used	in	the	treatment	of	many	cancers	
including	lymphoma	and	breast	cancer	and	autoimmune	disorders	is	
cyclophosphamide.	When	used	in	high	doses	for	the	treatment	of	cancer,	permanent	
damage	can	be	induced	due	to	the	heart	developing	structural	injury	(Madeddu,	C.	et	
al.,	2016).	Damage	that	could	be	induced	includes	congestive	heart	failure,	
myocardial	depression,	and	cardiac	tamponade,	which	is	a	fluid	buildup	between	
the	pericardium	(the	sac	surrounding	the	heart)	and	the	heart	muscle	(Chakraborty,	
Bhattacharjee,	&	Kamath,	2017).	Cardiac	tamponade,	as	well	as	other	damage,	puts	a	
lot	of	pressure	on	the	heart,	making	it	work	harder;	therefore,	the	heart	will	tire	
easier	and	will	be	susceptible	to	heart	failure.	Out	of	those	who	receive	a	high	dose	
of	cyclophosphamide,	20%	has	undergone	acute	cardiac	dysfunction	(Liu,	et	al.,	
2018).	Using	cyclophosphamide	in	high	doses	is	thought	to	increase	the	risk	of	heart	
failure	anywhere	from	7-28%	(Madeddu,	2016).	This	makes	cyclophosphamide	a	
type	1	chemotherapy	and	dependent	upon	dose.	It	is	thought	that	free	oxygen	
radicals	play	a	role	in	the	cardiotoxicity,	but	the	exact	mechanism	as	to	how	
cardiotoxicity	is	induced	is	not	known	(Higgins,	O’Halloran,	&	Chang,	2015).		
Despite	the	classification	of	a	type	1	chemotherapy,	the	odds	of	long-term	
cardiotoxicity	induced	by	cyclophosphamide	in	a	cancer	patient	are	relatively	rare	
and	usually	seen	when	the	dosage	is	over	140	mg/kg	before	a	bone	marrow	
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transplant	(Zamorano,	et	al.,	2016).	In	33%	of	patients	undergoing	bone	marrow	
transplantation	that	were	pretreated	with	cyclophosphamide,	there	were	ECG	
changes	showing	QT	prolongation	and	cardiac	arrhythmias	(Tamargo,	Caballero,	&	
Delpón,	2015).	An	ECG	detects	the	electrical	activity	of	the	ventricles	of	the	heart	as	
it	pumps	blood	throughout	the	body,	and	each	wave	is	labeled	as	P,	Q,	R,	S,	and	T,	
respectively.	When	the	heart	takes	longer	to	recharge,	or	refill	the	ventricles	with	
blood,	it	is	termed	a	QT	prolongation.		
This	change	in	the	electrical	activity	of	the	heart	can	lead	to	arrhythmias.	The	
use	of	cyclophosphamide	has	been	linked	to	many	different	heart	arrhythmias	such	
as	bradycardia,	atrioventricular	block,	atrial	fibrillation,	supraventricular	
tachycardias,	and	ventricular	tachycardia/fibrillation	(Zamorano,	et	al.,	2016).	
According	to	Tamargo,	Caballero,	and	Delpón,	7.9-10%	of	patients	administered	
with	a	high	dose	of	cyclophosphamide	show	atrial	and	ventricular	tachyarrhythmias	
24-72	hours	after	the	dose	(abnormal	rhythms	in	the	upper	or	lower	chambers	of	
the	heart,	respectively);	however,	it	disappears	spontaneously	within	a	7-day	time	
frame	(2015).	The	cardiac	manifestation	that	is	most	severe	and	occurs	in	less	than	
1-9%	of	those	who	used	high	doses	of	cyclophosphamide	is	hemorrhagic	necrotic	
perimyocarditis	(Emadi,	Jones,	&	Brodsky,	2009).	A	54-year-old	women	with	normal	
heart	function	was	given	cyclophosphamide	a	month	before	her	autologous	stem	
cell	transplantation	to	mobilize	her	peripheral	blood	hematopoietic	stem	cells,	but	
within	24	hours	after	her	surgery,	she	had	succumbed	to	cyclophosphamide-
induced	cardiotoxicity	(Martin,	et	al.,	2017).	According	to	Martin,	et	al.,	the	autopsy	
of	the	woman’s	heart	showed	moderate	hemorrhagic	pericarditis	and	intra-cavity	
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thrombus	(2017).	This	is	consistent	with	the	clinical	presentation	of	
cyclophosphamide-induced	cardiotoxicity,	which	is	congestive	heart	failure	that	
occurs	suddenly	(Martin,	et	al.,	2017).	Cardiotoxicity	is	typically	due	to	left	
ventricular	function	and	occurs	in	45%	of	those	who	undergo	bone	marrow	
transplants	(Emadi,	Jones,	&	Brodsky,	2009).	Cyclophosphamide	has	been	
connected	to	apoptosis	of	the	cardiomyocytes	and	damage	of	the	mitochondria,	as	
well	(Iqubal,	et	al.,	2019).	Cyclophosphamide’s	metabolites	induce	the	generation	of	
reactive	oxygen	species	in	the	mitochondria	and	cause	the	inflammation	of	heart	
cells	(Iqubal,	et	al.,	2019).		
	In	a	study	using	rat	cardiomyocytes,	the	cells	were	grown	overnight	and	
exposed	to	one	of	the	following:	cyclophosphamide,	4-hydroxycyclophosphamide,	
carboxyethylphosphoramide	mustard,	or	acrolein	(Kurauchi,	et	al.,	2017).	Moreover,	
the	cells	that	were	exposed	to	4-hydroxycyclophosphamide	and	acrolein	for	24-	and	
48-hour	periods	showed	myocardial	cytotoxicity	and	higher	levels	of	reactive	
oxygen	species	(produced	in	the	mitochondria)	than	in	the	controls	(Kurauchi,	et	al.,	
2017).	This	study	manifested	the	notion	that	the	cyclophosphamide	itself	was	not	
cytotoxic,	but	the	metabolites	from	the	cyclophosphamide	were	causing	the	damage	
to	the	heart	cells	(Kurachi,	et	al.,	2017).	Acrolein	is	a	metabolite	of	
cyclophosphamide	that	is	toxic	and	reactive;	therefore,	it	modifies	proteins	
substantially	and	induces	myocardial	injury	(Madeddu,	2016).	The	4-
hydroxycyclophosphamide	was	converted	to	acrolein,	creating	a	higher	
concentration	of	it	in	the	cell	and	an	even	greater	extent	of	damage	to	the	
cardiomyocytes	(Kurachi,	et	al.,	2017).		
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Phosphoramide	mustard	is	also	formed,	which	is	a	neoplastic	agent	that	
causes	tumor	death;	hence,	the	use	in	the	treatment	of	cancer	(Iqubal,	et	al.,	2019).	
As	shown	in	Figure	2,	4-hydro-cyclophosphamide	exists	with	aldophosphamide,	
which	breaks	down	into	phosphoramide	mustard	and	acrolein	in	the	body;	
moreover,	the	phosphoramide	mustard	is	useful	in	the	treatment	of	cancer	while	
the	acrolein	formed,	mentioned	above,	is	toxic	to	the	heart	in	many	ways	(Iqubal,	et	
al.,	2019).	Acrolein	activates	caspases	by	forming	an	adduct,	or	bond,	with	cysteine,	
which	then	causes	apoptosis	of	heart	cells	(Iqubal,	et	al.,	2019).	Acrolein	also	leads	
to	oxidative	stress	making	the	heart	work	harder,	and	thus	leading	to	heart	failure,	
and	potentially	death	(Iqubal,	et	al.,	2019).	As	shown	in	Figure	2,	the	formation	of	
acrolein	will	eventually	lead	to	immune	suppression,	cardiac	inflammation,	
endothelial	dysfunction	and	vasoconstriction,	or	cardiac	apoptosis	(Iqubal,	et	al.,	
2019).		
Cyclophosphamide	is	a	chemotherapy	that	is	also	used	before	transplants;	
although	this	case	is	rare,	it	goes	to	show	that	even	when	used	in	small	doses	for	
transplants,	cardiotoxicity	could	still	be	an	unwanted	side	effect	that	can	lead	to	
death.	The	woman’s	heart	was	healthy	going	into	surgery	and	all	the	scans	were	
normal,	but	once	the	cardiotoxicity	started,	it	could	not	be	stopped	from	killing	her.	
Cyclophosphamide	seems	to	have	a	lower	risk	of	irreversible	damage	to	the	heart,	
and	it	contains	2	elements	of	which	one	is	cardiotoxic	and	the	other	has	anticancer	
effects;	moreover,	research	has	shown	greater	promise	in	making	
cyclophosphamide	a	safer	treatment	option	compared	to	the	anthracyclines	that	
have	to	be	taken	with	something	else	to	try	to	prevent	or	lessen	the	cardiotoxic	
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effects	that	are	otherwise	unavoidable.	Cyclophosphamide	has	different	metabolites	
that	either	have	anticancer	effects	or	cardiotoxic	effects;	therefore,	creating	a	
treatment	that	does	not	have	the	cardiotoxic	effects	of	acrolein	but	has	the	
anticancer	effects	of	phosphoramide	mustard,	would	be	beneficial	to	many	who	are	
undergoing	transplants	and	to	those	fighting	their	battle	with	cancer.	
	
Tyrosine	Kinase	Inhibitors	
Tyrosine	kinases	are	enzymes	that	transfer	phosphate	onto	amino	acids	from	
ATP,	altering	intracellular	signaling	pathways	(Chaar,	Kamta,	&	Ait-Oudhia,	2018).	
However,	in	many	cancers,	including	breast	cancer,	the	enzyme	has	been	found	to	
be	overexpressed,	and	has	led	to	the	development	of	the	Tyrosine	Kinase	Inhibitors,	
or	TKIs	(Chaar,	Kamta,	&	Ait-Oudhia,	2018).	The	tyrosine	kinase	inhibitor	binds	to	
the	tyrosine	kinase	receptor	(TKR)	preventing	the	proliferation	of	cells	and	
enhancing	apoptosis,	but	as	with	most	chemotherapies,	the	TKIs	have	been	tied	to	
cardiotoxicity	(Chaar,	Kamta,	&	Ait-Oudhia,	2018).	With	TKI	use,	the	way	that	
cardiomyocytes	are	injured	varies	depending	upon	the	specific	TKI	taken	(Chaar,	
Kamta,	&	Ait-Oudhia,	2018).	Some	TKI’s	are	not	as	toxic	to	the	heart	as	others	
(Chaar,	Kamta,	&	Ait-Oudhia,	2018).	The	difference	in	the	mechanisms	between	the	
FDA	approved	TKIs	(greater	than	30)	that	make	some	toxic	to	the	heart	and	others	
not	toxic	is	still	not	understood	(Brown,	Ray,	&	Herrmann,	2019).	Any	pre-existing	
conditions	such	as	cardiac	disease,	diabetes,	and	hypertension,	and	genetics	all	
increase	the	chance	of	injury	to	the	heart	muscle	when	taking	TKIs	(Chaar,	Kamta,	&	
Ait-Oudhia,	2018).	
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TKIs	have	been	associated	with	mitochondrial	damage	due	to	the	inhibition	
of	kinases	that	were	not	targeted,	such	as	protein	kinase	A;	moreover,	this	can	lead	
to	the	hypertrophy	of	the	cardiomyocyte	(Chaar,	Kamta,	&	Ait-Oudhia,	2018).	QT	
prolongation,	as	mentioned	with	cyclophosphamide,	has	also	been	associated	with	
TKI	use	(Chaar,	Kamta,	&	Ait-Oudhia,	2018).	Acute	vascular	events	have	been	tied	to	
TKI	use,	which	can	lead	to	hypertension	and	damage	to	the	cardiomyocytes;	in	spite	
of	this,	not	all	TKIs	induce	hypertension	(Hermann,	et	al.,	2016).		
The	TKI	lapatinib	is	a	common	chemotherapy	used	in	the	treatment	of	breast	
cancer.	It	targets	the	human	epidermal	growth	factor	receptor	2	and	the	epidermal	
growth	factor	receptor,	and	it	has	been	speculated	that	the	drug	is	toxic	to	the	heart	
(Choi	&	Chang,	2017).	When	compared	with	other	chemotherapies,	though,	the	
lapatinib-induced	cardiotoxicity	rate	was	low	(Choi	&	Chang,	2017).		The	result	of	
several	studies	showed	no	significant	increase	in	the	risk	for	heart	issues	(Choi	&	
Chang,	2017).	However,	patients	are	still	at	risk,	so	there	is	still	careful	monitoring	
of	the	heart	during	the	course	of	treatment	(Choi	&	Chang,	2017).	Because	the	
incidences	of	those	with	lapatinib-induced	cardiotoxicity	are	typically	reversible	
and	the	risk	of	cardiotoxicity	is	low,	it	is	Type	II	Chemotherapy	(Jerusalem,	
Lancellotti,	&	Kim,	2019).	The	chance	of	the	development	of	cardiomyopathy	in	a	
patient	treated	with	lapatinib	is	1-2%	and	for	heart	failure,	the	chance	is	0.1-0.5%;	
furthermore,	it	has	the	lowest	rate	of	cardiotoxicity	(Brown,	Ray,	&	Herrmann,	
2019).	
Lapatinib	has	shown	to	be	an	effective	TKI	against	triple-negative	breast	
cancer	cells,	as	it	triggers	extensive	DNA	damage	(Abo-Zeid,	Abo-Elfadl,	&	Gamal-
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Eldeen,	2019).	Triple-negative	breast	cancer	is	an	aggressive	and	invasive	type	of	
breast	cancer	that	is	difficult	to	treat	(American	Cancer	Society,	2019).	This	type	
does	not	have	estrogen	receptors,	progesterone	receptors,	or	a	lot	of	human	
epidermal	growth	factor	receptors	2;	hence,	the	name,	triple	negative	(American	
Cancer	Society,	2019).	However,	triple-negative	breast	cancer	grows	and	spreads	
faster	than	other	breast	cancers	while	also	having	limited	treatment	options	and	a	
worse	outcome	(American	Cancer	Society,	2019).		
Lapatinib	has	been	thought	to	be	effective	as	a	single	agent	or	in	combination	
with	other	chemotherapies	for	those	with	breast	cancer	(Choi	&	Chang,	2017).	
Lapatinib	activates	the	5’	adenosine	monophosphate-activated	protein	kinase	
pathway;	furthermore,	this	pathway	inhibits	the	death	of	𝛼-induced	
cardiomyocytes,	so	the	therapy	may	have	a	cardioprotective	effect	(Choi	&	Chang,	
2017).	When	paired	with	other	chemotherapies	such	as	trastuzumab	and	the	
anthracyclines,	which	induce	cardiotoxicity,	lapatinib	may	protect	the	heart	from	
some	of	that	damage.	There	is,	however,	a	chance	of	developing	cardiotoxicity	with	
the	use	of	lapatinib,	but	the	overall	incidence	of	it	in	those	with	breast	cancer	is	low	
when	compared	with	trastuzumab	(Choi	&	Chang,	2017).	
In	a	meta-analysis	of	45	studies	including	patients	treated	with	lapatinib,	
cardiotoxicity	included	left	ventricular	dysfunction	and	arrhythmias	(Choi	&	Chang,	
2017).	In	the	studies,	over	600	of	the	patients	in	22	of	the	studies	had	cardiac	
adverse	events	and	58	people	in	5	of	the	studies	had	left	ventricular	dysfunction	
(Choi	&	Chang,	2017).	According	to	Choi	&	Chang,	overall,	2.70%	of	those	in	the	
studies	had	left	ventricular	dysfunction,	arrhythmia,	LVEF	(left	ventricular	ejection	
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fraction)	decrease,	and/or	other	cardiac	adverse	events	(2017).	LVEF	is,	with	each	
contraction,	the	amount	of	blood	pumped	out	of	the	heart.	In	a	study	of	patients	
with	breast	cancer,	3.0%	of	them	had	cardiotoxicity	(Choi	&	Chang,	2017).	The	risk	
factors	associated	with	lapatinib-induced	cardiotoxicity	include	previous	treatment	
with	anthracyclines,	older	than	65	years	old,	a	high	BMI,	previous	left	ventricular	
dysfunction,	arterial	hypertension,	and	previous	radiation	therapy	(Zamorano,	et	al.,	
2016).	The	effects	of	lapatinib	on	the	heart	when	used	to	treat	cancer	is	not	fully	
comprehended	and	more	research	needs	to	be	performed	in	order	to	better	
understand	and	verify	the	mechanisms	of	action	of	lapatinib	and	how	it	plays	into	
the	role	of	cardioprotective	and	cardiotoxic	agents.	
	 	
Antiestrogen	
	 Antiestrogen	is	another	class	of	chemotherapy	that	is	used	in	the	treatment	
of	breast	cancer.	A	study	using	older	patients	who	survived	breast	cancer	from	
Taiwan	discovered	that	the	use	of	antiestrogens	decreased	the	risk	of	developing	
lung	cancer	later	on	in	life	(Chu,	et	al.,	2017).	Estrogen	receptors	(alpha	and	beta)	
safeguard	the	central	nervous	system	and	the	cardiovascular	system;	however,	they	
have	also	been	involved	in	breast	cancer	and	cardiovascular	diseases	(Traboulsi,	et	
al.,	2017).	These	receptors	have	been	found	to	function	in	adult	cardiomyocytes,	and	
in	a	study	performed	on	rats,	the	destruction	of	the	estrogen	receptor	alpha	
promoted	ischemia	or	reperfusion	(Lorga,	et	al.,	2017).	Antiestrogens	work	by	
blocking	the	estrogenic	signaling	(Traboulsi,	et	al.,	2017).	These	drugs	act	as	
steroids	to	compete	for	the	estrogen	receptors,	and	therefore,	modify	the	activity	of	
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the	receptor	(Traboulsi,	et	al.,	2017).	Antiestrogens	compete	with	estradiol,	a	form	
of	estrogen	(the	female	sex	hormone),	for	the	estrogen	receptor	alpha	site	
(Traboulsi,	et	al.,	2017).	In	breast	cancer	cells	that	tested	positive	for	the	estrogen	
receptor	alpha,	there	was	an	increased	overall	amount	of	estrogen	receptor	alpha	
due	to	the	increase	of	the	product	produced	by	the	ubiquitin-proteasome	pathway	
(Traboulsi,	et	al.,	2017).		
	 Tamoxifen	is	a	common	chemotherapy	in	the	antiestrogen	class	that	is	used	
to	treat	breast	cancer.	Tamoxifen	opposes	the	proliferation	of	breast	cancer	cells;	
(Traboulsi,	et	al.,	2017).	Tamoxifen	has	been	thought	to	have	cardiovascular	effects	
that	are	favorable;	moreover,	these	effects	include	reducing	total	and	low-density	
lipoprotein	cholesterol	levels	while	increasing	the	amount	of		“good”	cholesterol,	
high-density	lipoprotein	(Khosrow-Khavar,	et	al.,	2017).	In	a	study	comparing	
aromatic	inhibitors	to	Tamoxifen,	there	was	a	34%	decreased	risk	of	developing	
ischemic	heart	disease	when	treated	with	Tamoxifen	rather	than	no	treatment;	
furthermore,	there	was	a	33%	decrease	in	risk	of	developing	any	tamoxifen-induced	
cardiovascular	events	(Khosrow-Khavar,	et	al.,	2017).	Likewise,	in	breast	cancer	
treatment,	there	was	a	26%	decreased	risk	of	myocardial	infarction	and	a	45%	
decrease	in	risk	of	death	due	to	myocardial	infarction	(Khosrow-Khavar,	et	al.,	
2017).	In	a	study	of	women	with	breast	cancer	who	were	either	treated	with	
anthracyclines	or	with	tamoxifen	displayed	the	protective	effects	that	tamoxifen	has	
on	the	heart,	as	the	troponin	1	(protein	that	controls	actin	and	myosin	in	the	heart)	
levels	stayed	the	same	in	the	treatment	group	treated	only	with	tamoxifen	and	in	
the	group	treated	with	both	anthracycline	and	tamoxifen;	on	the	other	hand,	the	
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group	treated	with	only	anthracyclines	had	an	increase	in	the	levels	(Silva,	et	al.,	
2017).		
	 	
PREVENTIVE	STRATEGIES/TREATMENT	OPTIONS	
	 With	the	use	of	chemotherapies	and	the	knowledge	of	the	cardiotoxicity	that	
comes	with	a	majority	of	them,	there	are	some	treatment	options	to	help	prevent	
the	cardiotoxicity	that	is	induced.	Potential	treatments	and	preventative	strategies	
include	fullenerol,	dexrazoxane,	carvedilol,	troponin,	and	statins.	
	 Fullenerol	has	been	studied	intensely,	and	a	lot	of	those	studies	have	found	
that	fullenerol	can	act	as	a	protective	agent	to	damage	induced	by	the	use	of	
doxorubicin	by	functioning	as	a	free	radical	scavenger	(Potočnik,	et	al.,	2017).	
Furthermore,	there	is	no	evidence	of	it	interfering	with	the	anti-cancer	activity	of	
doxorubicin	(Potočnik,	et	al.,	2017).	In	a	study	on	rats	with	colon	cancer,	the	
development	of	adenocarcinomas	was	significantly	reduced	in	the	group	treated	
with	just	doxorubicin	and	in	the	group	treated	with	fullenerol	before	being	treated	
with	doxorubicin	(Potočnik,	et	al.,	2017).	Therefore,	fullenerol	did	not	have	an	effect	
on	doxorubicin	treating	cancer.	Pretreating	the	rats	with	fullenerol	also	kept	
oxidation	at	a	normal	level,	while	doxorubicin	increases	oxidative	stress	in	the	heart	
(Potočnik,	et	al.,	2017).	Furthermore,	the	ECGs	of	rats	pretreated	were	normal	while	
those	just	treated	with	doxorubicin	show	lengthening	in	the	QRS	and	ST	waves	
(Potočnik,	Perše,	Cerar,	Injac,	&	Finderie,	2017).	Doxorubicin-induced	cardiotoxicity	
is	prevented	by	the	pretreatment	of	fullenerol,	as	it	acts	as	a	cardioprotective	agent	
and	resists	any	changes	that	doxorubicin	tries	to	induce	(Potočnik,	et	al.,	2017).	
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	 Dexrazoxane	is	an	iron-chelating	agent	that	reduces	cardiotoxicity	induced	
by	anthracyclines	significantly	for	solid	tumors	in	adults	and	for	leukemia	and	
Ewing’s	sarcoma	in	children	(Curigliano,	et	al.,	2012).	Dexrazoxane	is	also	a	
Topoisomerase	II𝛽	inhibitor,	and	it	is	the	most	studied	for	protection	against	
anthracycline-induced	cardiotoxicity;	furthermore,	it	does	so	without	inhibiting	the	
anticancer	effects	of	the	anthracycline	treatment	(Higgins,	O’Halloran,	&	Chang,	
2015).	The	American	Society	of	Clinical	Oncology	recommends	the	use	of	
Dexrazoxane	for	breast	cancer	to	act	as	a	cardioprotectant	against	the	toxicity	
induced	by	doxorubicin	(Curigliano,	et	al.,	2012).	Dexrazoxane	is	only	
recommended,	though,	if	the	patient	has	received	over	300	mg/𝑚)	of	doxorubicin	
(Higgins,	O’Halloran,	&	Chang,	2015).	A	meta-analysis	of	adult	patients	treated	with	
anthracyclines	demonstrated	a	reduced	risk	of	heart	failure	when	taking	
dexrazoxane	(Zamorano,	et	al.,	2016).	In	children,	dexrazoxane	was	found	to	protect	
the	heart	without	compromising	the	anticancer	effects	of	chemotherapies;	likewise,	
in	another	study,	the	development	of	cardiotoxicity	in	the	future	was	much	higher	in	
those	who	were	not	treated	with	dexrazoxane	(Reichardt,	et	al.,	2018).	Overall,	
dexrazoxane	is	a	promising	preventative	strategy	against	the	cardiotoxicity	that	is	
induced	by	chemotherapies,	specifically,	the	anthracyclines	and	doxorubicin.	
	 Carvedilol	is	a	beta-blocker	that	has	also	been	thought	to	prevent	any	cardiac	
damage	also	induced	by	doxorubicin	(Curigliano,	et	al.,	2012).	A	study	confirmed	
that	it	prevents	left	ventricular	dysfunction	and	has	reduced	mortality	in	those	
taking	doxorubicin	(Curigliano,	et	al.,	2012).	Carvedilol	has	also	been	shown	to	
maintain	calcium	homeostasis,	which	is	vital	to	the	contraction	of	the	heart	muscle,	
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and	decrease	oxidative	stress	(Godishala,	Yang,	&	Asnani,	2018).	Beta-blockers	have	
anti-apoptotic	and	antioxidant	effects,	which	decrease	the	damage	to	the	
mitochondria	(Godishala,	Yang,	&	Asnani,	2018).	In	another	study	performed	on	
patients	with	HER2-negative	breast	cancer	showed	that	there	was	no	cardiotoxicity	
or	decrease	in	left	ventricular	ejection	fracture	to	35%	among	the	group	treated	
with	carvedilol	(Avila,	et	al.,	2018).	HER2-negative	breast	cancer	does	not	have	an	
excess	of	the	human	epidermal	growth	factor	receptor	2	meaning	that	the	cancer	
does	not	respond	to	chemotherapies	that	target	HER2	(American	Cancer	Society,	
2019).	More	research	on	carvedilol	is	needed	to	determine	if	it	would	be	a	
preventative	strategy	that	would	save	cancer	patients	from	cardiotoxicity.		
	 Troponin	has	been	demonstrated	to	detect	chemotherapy-induced	
cardiotoxicity	long	before	the	drug	has	had	a	chance	to	decrease	the	left	ventricular	
ejection	fraction	(Curigliano,	et	al.,	2012).	In	patients	treated	with	trastuzumab,	
troponin	has	been	determined	to	distinguish	between	reversible	and	irreversible	
damage	induced;	moreover,	this	is	determined	by	the	detection	of	myocardial	cell	
necrosis	(Curigliano,	et	al.,	2012).	The	increase	of	troponin	levels	demonstrated,	in	a	
study	with	114	patients	who	received	a	high	dose	of	chemotherapy,	a	lower	
incidence	of	cardiotoxicity	in	the	future	(Zamorano,	et	al.,	2016).	Monitoring	the	
levels	of	troponin	in	the	body	during	the	chemotherapy	treatment	may	help	
determine	which	patients	are	at	risk	for	chemotherapy-induced	cardiotoxicity	in	the	
future.		
	 Statins	are	cholesterol	medications	that	decrease	the	cell’s	synthesis	of	
intrinsic	cholesterol	and	promote	the	uptake	of	serum	LDL	cholesterol,	and	they	
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may	be	just	as	potent	as	other	cardiotoxic	preventative	medications,	such	as	
dexrazoxane	(Henninger	&	Fritz,	2017).	There	was	a	stronger	cardioprotective	
potential	in	those	animals	treated	with	statins	than	in	those	treated	with	carvedilol	
(Henninger	&	Fritz,	2017).	They	have	also	shown	to	decrease	oxidative	damage;	
furthermore,	the	statins	stabilize	the	mitochondria	and	decrease	the	vascular	
inflammation	(Higgins,	O’Halloran,	&	Chang,	2015).		Statins	may	interfere	with	
NADPH	oxidase,	which	hinders	the	toxicity	induced	by	anthracyclines	(Henninger	&	
Fritz,	2017).	However,	these	effects	were	only	studied	on	acute	toxicity,	so	more	
studies	are	needed	for	those	who	develop	chronic	cardiotoxicity	(Henninger	&	Fritz,	
2017).	One	study	performed	did	demonstrate	that	statins	have	the	potential	to	
prevent	cardiotoxicity	induced	by	doxorubicin	whether	the	toxicity	was	acute,	
subacute,	or	chronic	(Henninger	&	Fritz,	2017).	Furthermore,	a	study	in	2012	of	
breast	cancer	patients	receiving	statins	during	the	course	of	their	chemotherapy	
displayed	a	significantly	lower	risk	of	heart	failure	(Henninger	&	Fritz,	2017).	
Statins	have	also	demonstrated	their	ability	to	improve	the	anti-tumor	efficiency	of	
doxorubicin	(Henninger	&Fritz,	2017).	The	use	of	statins	during	the	course	of	
chemotherapy	seems	to	be	cardioprotective	and	would	be	great	for	those	enduring	
the	harsh	chemotherapy	treatments.	
	
CONCLUSION	
Chemotherapies	are	widely	used	in	the	treatment	of	cancer,	and	although	
they	have	anticancer	effects,	the	drugs	are	so	potent,	that	they	are	also	affecting	the	
heart.	There	are	many	classes	of	chemotherapies	and	some	are	more	potent	than	
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others.	Anthracyclines	are	among	the	most	well-known	chemotherapies	due	to	the	
wide	range	of	cancers	they	are	used	to	treat,	but	they	also	tend	to	induce	
irreversible	damage	to	the	heart	that	ultimately	leads	to	heart	failure	and	death.	
Monoclonal	antibodies	are	known	for	their	cardioprotective	effects	on	the	heart.	
There	are	many	classes	of	chemotherapies	that	fall	between	the	anthracyclines	and	
the	monoclonal	antibodies	on	the	cardiotoxicity	scale.	Trastuzumab	is	among	those	
drugs	that	typically	cause	reversible	damage	to	the	heart,	unless	it’s	given	in	
addition	to	an	anthracycline	or	given	too	soon	after	anthracycline	treatment.	
Cancer,	unfortunately,	is	a	particularly	prevalent	disease,	so	the	effects	of	the	
treatment	used	is	of	utmost	importance	to	those	who	fight	the	difficult	battle	and	
come	out	alive.	For	someone	to	survive	cancer	and	chemotherapy	only	to	end	up	
with	chemotherapy-induced	cardiotoxicity,	that	is	still	losing	to	cancer.	Although,	
the	person	survived	cancer	the	first	time	around,	it	is	ironic	that	even	then,	cancer	
still	wins	because	the	treatment	used	is	harmful.	This	brings	about	the	importance	
of	weighing	the	risks	of	all	the	different	chemotherapy	options	and	deciding	which	
would	be	best	considering	the	chemotherapy’s	ability	to	kill	cancer	cells	while	also	
avoiding	irreversible	damage	to	the	heart.	It	also	puts	pressure	on	drug	companies	
and	scientists	to	create	a	drug	that	is	safer	than	current	chemotherapies	or	
something	that	can	be	used	to	help	prevent	cardiotoxicity	as	the	chemotherapy	is	
being	used.	Cancer	has	been	around	for	so	long,	and	there	is	still	not	a	medication	
that	can	treat	it	without	causing	other	complications.	A	preventative	medication	that	
has	extensive	research	and	has	been	shown	to	decrease	the	cardiotoxic	effects	that	
chemotherapies,	and	specifically,	anthracyclines,	have	on	the	heart	is	dexraxozone.	
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Carvedilol,	statins,	and	troponin	I	are	both	being	researched	to	prevent	and	detect	
chemotherapy-induced	cardiotoxicity.	Creating	a	treatment	that	is	safe	and	effective	
when	fighting	cancer	will	improve	the	lives	of	many	who	are	able	to	win	their	battle	
against	cancer.	
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